股本结构
单位：万股
| 公告日期 | 2023-05-11 | 2023-05-11 | 2023-03-30 | 2023-03-30 | 2022-12-22 | 2022-12-20 |
|---|---|---|---|---|---|---|
| 证券总股本 | 221.42 | 221.41 | 221.42 | 221.39 | 102.28 | 92.08 |
| 普通股本 | 221.42 | 221.41 | 221.42 | 221.39 | 102.28 | 92.08 |
| 优先股 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 其他 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 变动日期 | 2023-05-05 | 2023-03-31 | 2023-03-15 | 2022-12-31 | 2022-12-23 | 2022-12-21 |
注释：中概股证券总股本=普通股股本/
存托凭证比例
历史变动
| 公告日期 | 变动后普通股本（万股） | 变动后优先股（万股） | 变动原因 | 变动日期 |
|---|---|---|---|---|
| 2023-05-11 | 221.42 | 未披露 | 定期报告 | 2023-05-05 |
| 2023-05-11 | 221.41 | 未披露 |
更多>>
From January 1, 2023 to March 31, 2023
Release of restricted stock awards
Cash in lieu of fractional shares
Net share settlement of restricted stock awards
|
2023-03-31 |
| 2023-03-30 | 221.42 | 未披露 | 定期报告 | 2023-03-15 |
| 2023-03-30 | 221.39 | 未披露 |
更多>>
From December 31, 2021 to December 31, 2022
Release of restricted stock awards
Net share settlement of restricted stock awards
Stock issued under stock purchase plans
Conversion of Series A convertible preferred stock for common stock
Issuance of common stock and pre-funded warrants from March 2022 Securities Purchase Agreement, net of issuance costs of approximately $0.5 million
Issuance of common stock and pre-funded warrants from December 2022 Securities Purchase Agreement, net of commissions and issuance costs of approximately $1.3 million
Exercise of March 2022 Securities Purchase Agreement pre-funded warrants
Exercise of December 2022 Securities Purchase Agreement pre-funded warrants
Cash in lieu of fractional shares related to reverse stock split
|
2022-12-31 |
| 2022-12-22 | 102.28 | 未披露 |
更多>>
Common stock offered by the company 102,000 shares
|
2022-12-23 |
| 2022-12-20 | 92.08 | 未披露 |
更多>>
On December 19, 2022, HTG Molecular Diagnostics, Inc. (the "Company") filed a Certificate of Amended and Restated Certificate of Incorporation (the "Amendment") with the Secretary of State of the State of Delaware to effect a one-for-twelve reverse stock split of its outstanding common stock.
|
2022-12-21 |
| 2022-11-10 | 1104.99 | 未披露 | 定期报告 | 2022-11-03 |
| 2022-10-31 | 1105.00 | 未披露 | 定期报告 | 2022-10-26 |
| 2022-11-10 | 1104.81 | 未披露 |
更多>>
From June 30, 2022 to September 30, 2022
Release of restricted stock awards
Net share settlement of restricted stock awards
|
2022-09-30 |
| 2022-07-18 | 1104.81 | 未披露 | 定期报告 | 2022-07-15 |
| 2022-08-12 | 1104.60 | 未披露 |
更多>>
From March 31, 2022 to June 30, 2022
Release of restricted stock awards
Net share settlement of restricted stock awards
Stock issued under stock purchase plans
Exercise of pre-funded warrants
|
2022-06-30 |
| 2022-07-07 | 1104.60 | 未披露 | 定期报告 | 2022-06-15 |
| 2022-05-12 | 858.60 | 未披露 | 定期报告 | 2022-05-05 |
| 2022-05-12 | 858.33 | 未披露 |
更多>>
From January 1, 2022 to March 31, 2022
Conversion of Series A convertible preferred stock for common stock
Release of restricted stock awards
Net share settlement of restricted stock awards
Issuance of common stock from March 2022 Purchase Agreement, net of approximately $0.4 million of issuance costs
|
2022-03-31 |
| 2022-03-29 | 759.07 | 未披露 | 定期报告 | 2022-02-28 |
| 2022-03-29 | 758.81 | 2.38 |
更多>>
From December 31, 2020 to December 31, 2021
Release of restricted stock awards
Net share settlement of restricted stock awards
Stock issued under stock purchase plans
Issuance of common stock from ATM offering, net of commissions of approximately $0.3 million
Issuance of common stock in connection with LP Purchase Agreement
Exercise of pre-funded warrants
Exercise of stock options
|
2021-12-31 |
| 2021-11-10 | 756.78 | 未披露 | 定期报告 | 2021-11-05 |
| 2021-11-10 | 751.37 | 2.38 |
更多>>
From June 30, 2021 to September 30, 2021
Release of restricted stock awards
Net share settlement of restricted stock awards
Issuance of common stock in connection with LP Purchase Agreement
|
2021-09-30 |
| 2021-08-12 | 741.25 | 未披露 | 定期报告 | 2021-08-06 |
| 2021-08-12 | 741.15 | 2.38 |
更多>>
From March 31, 2021 to June 30, 2021
Release of restricted stock awards
Net share settlement of restricted stock awards
Stock issued under stock purchase plans
Issuance of common stock from ATM Offering, net of commissions of approximately $0.1 million
Exercise of pre-funded warrants
|
2021-06-30 |
| 2021-07-07 | 726.66 | 未披露 | 定期报告 | 2021-06-22 |
| 2021-05-13 | 627.27 | 未披露 | 定期报告 | 2021-05-07 |
| 2021-05-13 | 625.93 | 2.38 |
更多>>
From January 1, 2021 To March 31, 2021
Release of restricted stock awards
Net share settlement of restricted stock award
Issuance of common stock from ATM offering, net of commissions of approximately $0.2 million
Exercise of stock options
|
2021-03-31 |
| 2021-03-25 | 621.44 | 未披露 | 定期报告 | 2021-03-15 |
| 2021-03-25 | 520.00 | 2.38 |
更多>>
From December 31, 2019 to December 31, 2020
Release of restricted stock awards
Net share settlement of restricted stock award
Stock issued under stock purchase plans
Issuance of common stock from ATM offering, net of commissions and issuance costs of approximately $0.3 million
Issuance of Series A convertible preferred stock in private placement, net of issuance costs of approximately $37,000
Cancellation of common stock received in exchange for Series A convertible preferred stock
Issuance of Series A convertible preferred stock in exchange for outstanding common stock
Conversion of Series A convertible preferred stock for common stock
Shares issued, including stock compensation expense in connection with LP Purchase Agreement
Exercise of pre-funded warrants
Cash in lieu of fractional shares related to reverse stock split
|
2020-12-31 |
| 2020-11-19 | 473.97 | 未披露 |
更多>>
On November 19, 2020, HTG Molecular Diagnostics, Inc. (the “Company”) filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation (the “Amendment”) with the Secretary of State of the State of Delaware to (a) effect a one-for-fifteen reverse stock split of its outstanding common stock and (b) effect a reduction in the number of authorized shares of common stock from 200,000,000 shares to 26,666,667 shares. The Amendment will be effective at 5:00 p.m. Eastern Time on November 20, 2020. A series of alternate amendments to effect a reverse stock split and a concurrent reduction in the number of authorized shares of common stock were approved by the Company’s stockholders at the Company’s 2020 Annual Meeting of Stockholders held on August 19, 2020, and the specific one-for-fifteen reverse stock split and corresponding reduction in the number of authorized shares of common stock to 26,666,667 were subsequently approved by the Company’s Board of Directors on November 19, 2020.
|
2020-11-23 |
| 2020-11-10 | 7109.60 | 未披露 | 定期报告 | 2020-11-06 |
| 2020-11-10 | 7107.90 | 2.38 |
更多>>
From June 30, 2020 to September 30, 2020
Release of restricted stock awards
Net share settlement of restricted stock award
Issuance of common stock from ATM offering, net of commissions costs of $79,000
|
2020-09-30 |
| 2020-08-11 | 7068.17 | 未披露 | 定期报告 | 2020-08-07 |
| 2020-08-11 | 6709.37 | 2.38 |
更多>>
From March 31, 2020 to June 30, 2020
Conversion of Series A convertible preferred stock for common stock
Release of restricted stock awards
Net share settlement of restricted stock award
Stock issued under stock purchase plans
Issuance of common stock from ATM offering, net of commissions costs of $43,000
|
2020-06-30 |
| 2020-07-07 | 6709.37 | 未披露 | 定期报告 | 2020-06-22 |
| 2020-05-13 | 6221.35 | 未披露 | 定期报告 | 2020-05-01 |
| 2020-05-13 | 6219.61 | 5.13 |
更多>>
From January 1, 2020 to March 31, 2020
Issuance of Series A convertible preferred stock in private placement, net of issuance costs of $37,075
Issuance of Series A convertible preferred stock in exchange for outstanding commons stock
Release of restricted stock awards
Net share settlement of restricted stock award
Issuance of common stock from ATM offering, net of commissions and issuance costs of $174,000
Cancellation of common stock received in exchange for Series A convertible preferred stock
Exercise of pre-funded warrants
Issuance of common stock in connection with LP Purchase Agreement
|
2020-03-31 |
| 2020-03-25 | 5840.40 | 未披露 | 定期报告 | 2020-03-13 |
| 2020-03-25 | 5809.02 | 未披露 |
更多>>
From December 31, 2018 to December 31, 2019
Exercise of stock options
Release of restricted stock awards
Net share settlement of restricted stock award
Stock issued under stock purchase plans
Issuance of common stock from underwritten public and private offerings, net of underwriting discounts, commissions and issuance costs of $1.7 million
|
2019-12-31 |
| 2019-11-12 | 5804.19 | 未披露 | 定期报告 | 2019-11-05 |
| 2019-11-12 | 5803.12 | 未披露 |
更多>>
From June 30, 2019 to September 30, 2019
Release of restricted stock awards
Net share settlement of restricted stock awards
Issuance of common stock and warrants from the 2019 public and private offerings, net of issuance costs of $1.7 million
|
2019-09-30 |
| 2019-09-24 | 5418.40 | 未披露 | 定期报告 | 2019-09-24 |
| 2019-08-06 | 2872.02 | 未披露 | 定期报告 | 2019-08-02 |
| 2019-08-06 | 2870.70 | 未披露 |
更多>>
From March 31, 2019 to June 30, 2019
Exercise of stock options
Release of restricted stock awards
Net share settlement of restricted stock awards
Stock issued under stock purchase plans
|
2019-06-30 |
| 2019-07-02 | 2870.60 | 未披露 | 定期报告 | 2019-06-15 |
| 2019-05-09 | 2864.32 | 未披露 | 定期报告 | 2019-05-03 |
| 2019-05-09 | 2861.66 | 未披露 |
更多>>
From December 31,2018 to March 31, 2019
Exercise of stock options
Release of restricted stock awards
Net share settlement of restricted stock awards
|
2019-03-31 |
| 2019-03-07 | 2860.60 | 未披露 | 定期报告 | 2019-03-01 |
| 2019-03-07 | 2858.54 | 未披露 |
更多>>
From December 31,2017 to December 31,2018
Exercise of stock options
Release of restricted stock awards
Net share settlement of restricted stock awards
Stock issued under stock purchase plans
Issuance of common stock from ATM offering, net of issuance costs of approximately $17,000
Issuance of common stock from underwritten public offering, net of issuance costs of approximately $2.6 million
|
2018-12-31 |
| 2018-11-08 | 2849.58 | 未披露 | 定期报告 | 2018-11-02 |
| 2018-11-08 | 2847.93 | 未披露 |
更多>>
From January 1, 2018 to September 30, 2018
Exercise of stock options
Release of restricted stock awards
Net share settlement of restricted stock awards
Stock issued under stock purchase plans
Issuance of common stock from ATM offering, net of issuance costs of approximately $17,000
Issuance of common stock from underwritten public offering, net of issuance costs of approximately $2.6 million
|
2018-09-30 |
| 2018-08-09 | 2842.17 | 未披露 | 定期报告 | 2018-08-01 |
| 2018-08-09 | 2841.45 | 未披露 |
更多>>
From January 1, 2018 to June 30, 2018
Exercise of stock options
Vesting of restricted stock awards
Net share settlement of restricted stock award
Issuance of common stock from ATM Offering, net of issuance costs of $17,000
Issuance of common stock from underwritten public offering, net of issuance costs of $2.6 million
|
2018-06-30 |
| 2018-07-03 | 2841.23 | 未披露 | 定期报告 | 2018-06-18 |
| 2018-07-03 | 2837.22 | 未披露 | 定期报告 | 2018-06-08 |
| 2018-05-10 | 2837.11 | 未披露 | 定期报告 | 2018-05-04 |
| 2018-05-10 | 2835.89 | 未披露 |
更多>>
From December 31, 2017 to March 31, 2018
Exercise of stock options
Vesting of restricted stock awards
Net share settlement of restricted stock award
Issuance of common stock from ATM Offering, net of issuance costs of $17,000
Issuance of common stock from underwritten public offering, net of issuance costs of $2.6 million
|
2018-03-31 |
| 2018-03-23 | 2835.58 | 未披露 | 定期报告 | 2018-03-16 |
| 2018-03-23 | 1392.98 | 未披露 |
更多>>
from December 31, 2016 to December 31, 2017
Exercise of stock options
Vesting of restricted stock units
Stock issued under stock purchase plan
Issuance of common stock from ATM Offering, net of issuance costs of $0.8 million
|
2017-12-31 |
| 2017-11-07 | 1250.72 | 未披露 |
更多>>
From January 1, 2017 To September 30, 2017
Exercise of stock options
Vesting of restricted stock units
Stock issued under stock purchase plan
Issuance of common stock from ATM offering, net of issuance costs of $0.7 million
|
2017-09-30 |
| 2017-08-08 | 1144.84 | 未披露 | 定期报告 | 2017-08-04 |
| 2017-08-08 | 1135.83 | 未披露 |
更多>>
From January 1, 2017 to June 30, 2017
Exercise of stock options
Vesting of restricted stock units
Employee stock purchase plan
Issuance of common stock from the ATM Offering, net of issuance costs of $0.7 million
Retirement of treasury stock
|
2017-06-30 |
| 2017-07-03 | 1064.15 | 未披露 | 定期报告 | 2017-06-16 |
| 2017-07-03 | 1059.65 | 未披露 | 定期报告 | 2017-06-05 |
| 2017-05-15 | 952.58 | 未披露 | 定期报告 | 2017-05-05 |
| 2017-05-15 | 806.07 | 未披露 |
更多>>
from January 1, 2017 to March 31, 2017
Vesting of restricted stock units
Retirement of treasury stock
|
2017-03-31 |
| 2017-03-23 | 805.25 | 未披露 | 定期报告 | 2017-03-17 |
| 2017-03-23 | 793.86 | 未披露 |
更多>>
from December 31, 2015 to December 31, 2016
Stock issued for payment of 2015 annual bonus
Exercise of stock options
Vesting of restricted stock units
Employee stock purchase plan
Stock issued for private investment
|
2016-12-31 |
| 2016-11-14 | 706.53 | 未披露 | 定期报告 | 2016-11-04 |
| 2016-11-14 | 705.89 | 未披露 |
更多>>
From January 1, 2016 to September 30, 2016
Stock issued for payment of 2015 annual bonus
Exercise of stock options
Stock-based compensation expense
Employee stock purchase plan purchases
|
2016-09-30 |
| 2016-08-09 | 705.10 | 未披露 |
更多>>
from January 1, 2016 to June 30, 2016
Stock issued for payment of 2015 annual bonus
Exercise of stock options
Stock-based compensation expense
Employee stock purchase plan purchases
|
2016-06-30 |
| 2016-07-13 | 705.00 | 未披露 | 定期报告 | 2016-06-29 |
| 2016-05-12 | 700.90 | 未披露 | 定期报告 | 2016-05-06 |
| 2016-05-12 | 700.49 | 未披露 |
更多>>
from January 1, 2016 to March 31, 2016
Stock issued for payment of 2015 annual bonus
Stock-based compensation expense
|
2016-03-31 |
| 2016-03-25 | 697.74 | 未披露 | 定期报告 | 2016-03-18 |
| 2016-03-25 | 684.42 | 未披露 |
更多>>
from December 31, 2014 to December 31, 2015
Exercise of stock options
Stock issued under stock purchase plan
Settlement of outstanding principal and accrued interest on convertible notes by issuance of common stock
Conversion of preferred stock into common stock at initial public offering
Issuance of common stock from initial public offering net of issuance costs of $5.9 million
On April 27, 2015, the Company effected a one-for-107.39 reverse stock split of its outstanding common stock.
|
2015-12-31 |
| 2015-11-12 | 683.99 | 未披露 |
更多>>
from January 1, 2015 to September 30, 2015
Conversion of preferred stock into common stock at initial public offering
Exercise of stock options
Settlement of outstanding principal and accrued interest on convertible notes by issuance of common stock
Issuance of common stock from initial public offering net of issuance costs of $5.9 million
Exercise of Series D and Series E warrants
A one-for-107.39 reverse stock split of our common stock effected on April 27, 2015.
|
2015-09-30 |
| 2015-08-07 | 682.74 | 未披露 |
更多>>
From January 1, 2015 to June 30, 2015
Exercise of stock options
Settlement of outstanding principal and accrued interest on convertible notes by issuance of common stock
Conversion of preferred stock into common stock at initial public offering
Issuance of common stock from initial public offering net of issuance costs of $5.9 million
Exercise of Series D and Series E warrants
A one-for-107.39 reverse stock split of our common stock effected on April 27, 2015.
|
2015-06-30 |
| 2015-06-08 | 682.60 | 未披露 | 定期报告 | 2015-06-01 |
| 2015-05-06 | 673.60 | 未披露 |
更多>>
1. the conversion of all our outstanding redeemable convertible preferred stock into an aggregate of 2,126,982 shares of common stock in connection with the closing of this offering;
2. a one-for-107.39 reverse stock split of our common stock effected on April 27, 2015.
|
2015-05-06 |
| 2015-06-08 | 33.38 | 21679.16 |
更多>>
from January 1, 2015 to March 31, 2015
Exercise of Series E warrants
Exercise of stock options
|
2015-03-31 |
| 2015-04-28 | 33.26 | 21684.00 |
更多>>
from December 31, 2013 to December 31, 2014
Issuance of preferred stock Series E, net of issuance cost of $170,546
Exercise of Series D warrants
Exercise of Series E warrants
Optional conversion of preferred stock to common
|
2014-12-31 |
| 2014-12-30 | 1140.98 | 23823.23 |
更多>>
from December 31, 2013 to September 30, 2014
Issuance of preferred stock Series E, net of issuance cost of $126,206
Exercise of Series E warrants
Exercise of stock options
|
2014-09-30 |
From January 1, 2023 to March 31, 2023
Release of restricted stock awards
Cash in lieu of fractional shares
Net share settlement of restricted stock awards
From December 31, 2021 to December 31, 2022
Release of restricted stock awards
Net share settlement of restricted stock awards
Stock issued under stock purchase plans
Conversion of Series A convertible preferred stock for common stock
Issuance of common stock and pre-funded warrants from March 2022 Securities Purchase Agreement, net of issuance costs of approximately $0.5 million
Issuance of common stock and pre-funded warrants from December 2022 Securities Purchase Agreement, net of commissions and issuance costs of approximately $1.3 million
Exercise of March 2022 Securities Purchase Agreement pre-funded warrants
Exercise of December 2022 Securities Purchase Agreement pre-funded warrants
Cash in lieu of fractional shares related to reverse stock split
Common stock offered by the company 102,000 shares
On December 19, 2022, HTG Molecular Diagnostics, Inc. (the "Company") filed a Certificate of Amended and Restated Certificate of Incorporation (the "Amendment") with the Secretary of State of the State of Delaware to effect a one-for-twelve reverse stock split of its outstanding common stock.
From June 30, 2022 to September 30, 2022
Release of restricted stock awards
Net share settlement of restricted stock awards
From March 31, 2022 to June 30, 2022
Release of restricted stock awards
Net share settlement of restricted stock awards
Stock issued under stock purchase plans
Exercise of pre-funded warrants
From January 1, 2022 to March 31, 2022
Conversion of Series A convertible preferred stock for common stock
Release of restricted stock awards
Net share settlement of restricted stock awards
Issuance of common stock from March 2022 Purchase Agreement, net of approximately $0.4 million of issuance costs
From December 31, 2020 to December 31, 2021
Release of restricted stock awards
Net share settlement of restricted stock awards
Stock issued under stock purchase plans
Issuance of common stock from ATM offering, net of commissions of approximately $0.3 million
Issuance of common stock in connection with LP Purchase Agreement
Exercise of pre-funded warrants
Exercise of stock options
From June 30, 2021 to September 30, 2021
Release of restricted stock awards
Net share settlement of restricted stock awards
Issuance of common stock in connection with LP Purchase Agreement
From March 31, 2021 to June 30, 2021
Release of restricted stock awards
Net share settlement of restricted stock awards
Stock issued under stock purchase plans
Issuance of common stock from ATM Offering, net of commissions of approximately $0.1 million
Exercise of pre-funded warrants
From January 1, 2021 To March 31, 2021
Release of restricted stock awards
Net share settlement of restricted stock award
Issuance of common stock from ATM offering, net of commissions of approximately $0.2 million
Exercise of stock options
From December 31, 2019 to December 31, 2020
Release of restricted stock awards
Net share settlement of restricted stock award
Stock issued under stock purchase plans
Issuance of common stock from ATM offering, net of commissions and issuance costs of approximately $0.3 million
Issuance of Series A convertible preferred stock in private placement, net of issuance costs of approximately $37,000
Cancellation of common stock received in exchange for Series A convertible preferred stock
Issuance of Series A convertible preferred stock in exchange for outstanding common stock
Conversion of Series A convertible preferred stock for common stock
Shares issued, including stock compensation expense in connection with LP Purchase Agreement
Exercise of pre-funded warrants
Cash in lieu of fractional shares related to reverse stock split
On November 19, 2020, HTG Molecular Diagnostics, Inc. (the “Company”) filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation (the “Amendment”) with the Secretary of State of the State of Delaware to (a) effect a one-for-fifteen reverse stock split of its outstanding common stock and (b) effect a reduction in the number of authorized shares of common stock from 200,000,000 shares to 26,666,667 shares. The Amendment will be effective at 5:00 p.m. Eastern Time on November 20, 2020. A series of alternate amendments to effect a reverse stock split and a concurrent reduction in the number of authorized shares of common stock were approved by the Company’s stockholders at the Company’s 2020 Annual Meeting of Stockholders held on August 19, 2020, and the specific one-for-fifteen reverse stock split and corresponding reduction in the number of authorized shares of common stock to 26,666,667 were subsequently approved by the Company’s Board of Directors on November 19, 2020.
From June 30, 2020 to September 30, 2020
Release of restricted stock awards
Net share settlement of restricted stock award
Issuance of common stock from ATM offering, net of commissions costs of $79,000
From March 31, 2020 to June 30, 2020
Conversion of Series A convertible preferred stock for common stock
Release of restricted stock awards
Net share settlement of restricted stock award
Stock issued under stock purchase plans
Issuance of common stock from ATM offering, net of commissions costs of $43,000
From January 1, 2020 to March 31, 2020
Issuance of Series A convertible preferred stock in private placement, net of issuance costs of $37,075
Issuance of Series A convertible preferred stock in exchange for outstanding commons stock
Release of restricted stock awards
Net share settlement of restricted stock award
Issuance of common stock from ATM offering, net of commissions and issuance costs of $174,000
Cancellation of common stock received in exchange for Series A convertible preferred stock
Exercise of pre-funded warrants
Issuance of common stock in connection with LP Purchase Agreement
From December 31, 2018 to December 31, 2019
Exercise of stock options
Release of restricted stock awards
Net share settlement of restricted stock award
Stock issued under stock purchase plans
Issuance of common stock from underwritten public and private offerings, net of underwriting discounts, commissions and issuance costs of $1.7 million
From June 30, 2019 to September 30, 2019
Release of restricted stock awards
Net share settlement of restricted stock awards
Issuance of common stock and warrants from the 2019 public and private offerings, net of issuance costs of $1.7 million
From March 31, 2019 to June 30, 2019
Exercise of stock options
Release of restricted stock awards
Net share settlement of restricted stock awards
Stock issued under stock purchase plans
From December 31,2018 to March 31, 2019
Exercise of stock options
Release of restricted stock awards
Net share settlement of restricted stock awards
From December 31,2017 to December 31,2018
Exercise of stock options
Release of restricted stock awards
Net share settlement of restricted stock awards
Stock issued under stock purchase plans
Issuance of common stock from ATM offering, net of issuance costs of approximately $17,000
Issuance of common stock from underwritten public offering, net of issuance costs of approximately $2.6 million
From January 1, 2018 to September 30, 2018
Exercise of stock options
Release of restricted stock awards
Net share settlement of restricted stock awards
Stock issued under stock purchase plans
Issuance of common stock from ATM offering, net of issuance costs of approximately $17,000
Issuance of common stock from underwritten public offering, net of issuance costs of approximately $2.6 million
From January 1, 2018 to June 30, 2018
Exercise of stock options
Vesting of restricted stock awards
Net share settlement of restricted stock award
Issuance of common stock from ATM Offering, net of issuance costs of $17,000
Issuance of common stock from underwritten public offering, net of issuance costs of $2.6 million
From December 31, 2017 to March 31, 2018
Exercise of stock options
Vesting of restricted stock awards
Net share settlement of restricted stock award
Issuance of common stock from ATM Offering, net of issuance costs of $17,000
Issuance of common stock from underwritten public offering, net of issuance costs of $2.6 million
from December 31, 2016 to December 31, 2017
Exercise of stock options
Vesting of restricted stock units
Stock issued under stock purchase plan
Issuance of common stock from ATM Offering, net of issuance costs of $0.8 million
From January 1, 2017 To September 30, 2017
Exercise of stock options
Vesting of restricted stock units
Stock issued under stock purchase plan
Issuance of common stock from ATM offering, net of issuance costs of $0.7 million
From January 1, 2017 to June 30, 2017
Exercise of stock options
Vesting of restricted stock units
Employee stock purchase plan
Issuance of common stock from the ATM Offering, net of issuance costs of $0.7 million
Retirement of treasury stock
from January 1, 2017 to March 31, 2017
Vesting of restricted stock units
Retirement of treasury stock
from December 31, 2015 to December 31, 2016
Stock issued for payment of 2015 annual bonus
Exercise of stock options
Vesting of restricted stock units
Employee stock purchase plan
Stock issued for private investment
From January 1, 2016 to September 30, 2016
Stock issued for payment of 2015 annual bonus
Exercise of stock options
Stock-based compensation expense
Employee stock purchase plan purchases
from January 1, 2016 to June 30, 2016
Stock issued for payment of 2015 annual bonus
Exercise of stock options
Stock-based compensation expense
Employee stock purchase plan purchases
from January 1, 2016 to March 31, 2016
Stock issued for payment of 2015 annual bonus
Stock-based compensation expense
from December 31, 2014 to December 31, 2015
Exercise of stock options
Stock issued under stock purchase plan
Settlement of outstanding principal and accrued interest on convertible notes by issuance of common stock
Conversion of preferred stock into common stock at initial public offering
Issuance of common stock from initial public offering net of issuance costs of $5.9 million
On April 27, 2015, the Company effected a one-for-107.39 reverse stock split of its outstanding common stock.
from January 1, 2015 to September 30, 2015
Conversion of preferred stock into common stock at initial public offering
Exercise of stock options
Settlement of outstanding principal and accrued interest on convertible notes by issuance of common stock
Issuance of common stock from initial public offering net of issuance costs of $5.9 million
Exercise of Series D and Series E warrants
A one-for-107.39 reverse stock split of our common stock effected on April 27, 2015.
From January 1, 2015 to June 30, 2015
Exercise of stock options
Settlement of outstanding principal and accrued interest on convertible notes by issuance of common stock
Conversion of preferred stock into common stock at initial public offering
Issuance of common stock from initial public offering net of issuance costs of $5.9 million
Exercise of Series D and Series E warrants
A one-for-107.39 reverse stock split of our common stock effected on April 27, 2015.
1. the conversion of all our outstanding redeemable convertible preferred stock into an aggregate of 2,126,982 shares of common stock in connection with the closing of this offering;
2. a one-for-107.39 reverse stock split of our common stock effected on April 27, 2015.
from January 1, 2015 to March 31, 2015
Exercise of Series E warrants
Exercise of stock options
from December 31, 2013 to December 31, 2014
Issuance of preferred stock Series E, net of issuance cost of $170,546
Exercise of Series D warrants
Exercise of Series E warrants
Optional conversion of preferred stock to common
from December 31, 2013 to September 30, 2014
Issuance of preferred stock Series E, net of issuance cost of $126,206
Exercise of Series E warrants
Exercise of stock options